title: A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome.
abstract: The study was performed in 428 patients, of whom 216 were women. The median age was 36.5 (16-75) years and the median weight 67 (42-118) kg. The complaints were registered on a 10-cm-long linear analogue scale by the patients and the physicians. The patients were given coded identical-appearing tablets of placebo and different doses of trimipramine (Surmontil, Rhône-Poulenc) and randomized into groups A-E. During the 6 weeks of treatment the grades of complaints were reduced to about the half of pretreatment levels. The groups treated with trimipramine (groups A-D) felt significantly more improved than the group receiving placebo (group E). The side effect of tiredness was somewhat more pronounced 1-2 weeks after start with 50 mg trimipramine in the evening than in the groups receiving placebo and lower dose schedules of trimipramine.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000523:psychology; D003863:Depression / Q000188:drug therapy; D003984:Dibenzazepines / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D005222:Mental Fatigue / Q000188:drug therapy; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014299:Trimipramine / Q000008:administration & dosage* / Q000009:adverse effects; D014839:Vomiting / Q000188:drug therapy
chemical_list: D003984:Dibenzazepines; D014299:Trimipramine